Novel biomarkers for prostate cancer: an evidence‐based review for use in clinical practice
VM Narayan, BR Konety… - International Journal of …, 2017 - Wiley Online Library
Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …
parameters are limited in their ability to differentiate between these cases, and there is …
Novel biomarkers for prostate cancer: An evidence‐based review for use in clinical practice
VM Narayan, BR Konety, C Warlick - International Journal of Urology, 2017 - infona.pl
Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …
parameters are limited in their ability to differentiate between these cases, and there is …
Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice
VM Narayan, BR Konety… - International journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …
parameters are limited in their ability to differentiate between these cases, and there is …
Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
VM Narayan, BR Konety… - International Journal of …, 2017 - search.ebscohost.com
Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …
parameters are limited in their ability to differentiate between these cases, and there is …
Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
VM Narayan, BR Konety, C Warlick - International Journal of …, 2017 - europepmc.org
Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …
parameters are limited in their ability to differentiate between these cases, and there is …
Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice
VM Narayan, BR Konety, C Warlick - International Journal of …, 2017 - experts.umn.edu
Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …
parameters are limited in their ability to differentiate between these cases, and there is …